OpenAI has signed agreements with Abu Dhabi entities ADNOC, G42, Mubadala, and others to deploy its AI technology across energy, government, and investment sectors. The AI lab is also pursuing a new $20 billion funding round co-led by UAE investors, reflecting the region's growing role in AI development. CEO Sam Altman highlighted the UAE's commitment to safe and responsible AI innovation. These partnerships aim to integrate AI into public and private sectors, including government policy translation and investment analysis, positioning the UAE as a global AI hub.
OpenAI's expansion in Abu Dhabi is the subject, with Pluang's Technology sector data providing market context as of Nov 02, 2026 18:11 WIB. Among 150 priced Technology-sector US stocks tradable on Pluang, 102 rose and 34 fell today. Notable movers include CIFR at USD 7.51 with a 3.02% increase, NBIS at USD 158.65 up 2.95%, and APLD at USD 18.34 rising 2.92%.
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
